All assets associated with the tag: EpiPen
Federal regulators declined to approve a nasal spray from a San Diego company to treat severe allergic reactions late Tuesday, calling for more research on what would have been the first alternative to injections using devices such as an EpiPen. A Raleigh firm also has a nasal spray alternative under development.
Claims related to health and healthcare account for most of PolitiFact North Carolina's top-read stories of the year.
By Paul Specht, PolitiFact reporter
Bryn Pharma, which is developing a nasal spray to counteract life-threatening allergic reactions known as anaphylaxis, says it will move toward securing FDA approval for its product and plan to commercialize it after raising $17.5 million in new financing.
Widespread manufacturing problems are causing a shortage of EpiPens across the country. That means filling prescriptions for potentially life-saving medication to treat allergic reactions is becoming a concern for some families.
Monica Laliberte, WRAL executive producer/consumer reporter
When people think of tick-borne illnesses, Lyme disease and Rocky Mountain spotted fever come to mind.
Monica Laliberte, 5 On Your Side
A Raleigh-based life science company raised $17.2 million in a private equity offering, according to a securities filing.
The Food and Drug Administration on Thursday approved the first generic version of EpiPen, providing new competition that could help drive down the cost of a lifesaving product that had become a notorious symbol of high drug prices.
Sheila Kaplan, New York Times